riferminogene pecaplasmid
Gene therapyexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 1999 (NCT01157156)
Timeline
Indications
Mechanism of action
- Acidic fibroblast growth factorSupplementation
FGF1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108293 ↗
Also known as
- riferminogene pecaplasmid
- riferminogene pecaplasmid
- xrp0038
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00566657 | Phase 3 | Nov 1, 2007 | Sanofi |
| NCT01157871 | Phase 2 | Jun 1, 2004 | Sanofi |
| NCT00798005 | Phase 2 | Jun 1, 2002 | Sanofi |
| NCT00368797 | Phase 2 | Mar 1, 2002 | Sanofi |
| NCT01157143 | Phase 1 | Jan 1, 2002 | Sanofi |
| NCT01157156 | Phase 1 | Jun 1, 1999 | Sanofi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 6 | 6 | 3 | 1999 |
1 organizations
Page 1 / 1